Argentina
Hepatitis B
Download HBV dataHBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
System for monitoring testing and treatment
Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Not Adopted
HBV testing policy
Universal
No patient co-pays for HBsAg testing
Partially Adopted
National treatment guidelines exist
Adopted
Simplified care: No treatment co-pays
Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
System for monitoring testing and treatment
Adopted
Registration of originator HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Not Adopted
HCV testing policy
Universal
No patient co-pays for anti-HCV testing
Partially Adopted
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Public budget line for testing and treatment
Adopted
Hepatitis C
Download HCV dataHBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
System for monitoring testing and treatment
Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Eligible for HBV generic medicines
Licensed point-of-care PCR testing to detect HBV
Not Adopted
HBV testing policy
Universal
No patient co-pays for HBsAg testing
Partially Adopted
National treatment guidelines exist
Adopted
Simplified care: No treatment co-pays
Adopted
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
System for monitoring testing and treatment
Adopted
Registration of originator HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Not Adopted
HCV testing policy
Universal
No patient co-pays for anti-HCV testing
Partially Adopted
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
Simplified care: No treatment co-pays
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
Yes
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
Most (61-100%)
Public budget line for testing and treatment
Adopted
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
Hepatitis related deaths (national)
Modelled
HBV
1,012
2019
(755 - 1,348)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
HBV
838
2018
Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis Argentina
HBV chart
Modelled
HCV
3,527
2019
(2,823 - 4,327)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
HCV
3,730
2019
Dirección de Respuesta al VIH, ITS, Hepatitis Virales y Tuberculosis Argentina
HCV chart
Prevalence < 5
HBV
0.01
(%)
2020, latest modelled
(0.01 - 0.02(%))
WHO
No. of syringes/PWID/year
Survey/surveillance
No data available
Eligible for HBV generic medicines